
Ajax Therapeutics
Ajax developed JAK2 inhibitors for blood cancers before Eli Lilly acquired it.

Ajax developed JAK2 inhibitors for blood cancers before Eli Lilly acquired it.
Ajax Therapeutics was a biopharmaceutical company that developed next-generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera. It applied structural biology and computational chemistry to design selective therapies, and its lead asset, AJ1-11095, was an investigational once-daily oral, first-in-class Type II JAK2 inhibitor evaluated in the Phase 1 AJX-101 trial in patients with myelofibrosis previously treated with a Type I JAK2 inhibitor.
On April 27, 2026, Eli Lilly and Company announced a definitive agreement to acquire Ajax in an all-cash deal worth up to 2.3 billion US dollars, including an upfront payment and clinical and regulatory milestone payments. Ajax became a wholly-owned Lilly subsidiary, its website now redirects to Lilly, and AJ1-11095 continued in development under Lilly.
Companies similar to Ajax Therapeutics include Ajax Health, Accent Therapeutics, eXIthera Pharmaceuticals and Acylin Therapeutics.
Ajax Therapeutics was founded in 2019.
Ajax Therapeutics' headquarters is located in New York City, NY, US.
As of Apr 27, 2026, Ajax Therapeutics has disclosed funding of $143M (USD). Undisclosed round amounts are excluded.

Ajax Health
ajaxhealth.com

Accent Therapeutics
accenttx.com
eXIthera Pharmaceuticals
exithera.com
Acylin Therapeutics

Akebia Therapeutics
akebia.com

Agentix
agentixcorp.com

Apexian Pharmaceuticals
apexianpharma.com

JDP Therapeutics

Jacobio Pharma
jacobiopharma.com

Aether Therapeutics

Initial Therapeutics
initialtx.com
KinaRx
kinarx.com

Arrakis Therapeutics
arrakistx.com
Altiris Therapeutics
Axikin Pharmaceuticals
axikin.com